A Phase II Study Utilizing Gemcitabine and Cisplatinum in Patients With Renal Cell Carcinoma
OBJECTIVES:
- Assess the response rate of patients with metastatic renal cell carcinoma treated with
gemcitabine and cisplatin.
- Assess toxicity of this regimen in these patients.
OUTLINE: Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and cisplatin
IV over 60 minutes on day 15. Courses repeat every 28 days in the absence of disease
progression or unacceptable toxicity.
Patients are followed every 4 months.
PROJECTED ACCRUAL: Approximately 29-38 patients will be accrued for this study.
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Assess the response rate of patients with metastatic renal cell carcinoma treated with gemcitabine and cisplatin.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
No
Scot C. Remick, MD
Principal Investigator
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
United States: Federal Government
CWRU3897
NCT00003928
January 1999
April 2006
Name | Location |
---|---|
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center | Cleveland, Ohio 44106-5065 |